Last reviewed · How we verify

Hangzhou Sciwind Biosciences Co., Ltd. — Portfolio Competitive Intelligence Brief

Hangzhou Sciwind Biosciences Co., Ltd. pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ecnoglutide Low Dosage Ecnoglutide Low Dosage phase 3 GLP-1 receptor agonist GLP-1R Diabetes
Ecnoglutide High Dosage Ecnoglutide High Dosage phase 3 GLP-1 receptor agonist GLP-1R Diabetes
Ecnoglutide Medium Dosage Ecnoglutide Medium Dosage phase 3 GLP-1 receptor agonist GLP-1R Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amsterdam UMC, location VUmc · 1 shared drug class
  2. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  3. Astellas Pharma Inc · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · 1 shared drug class
  6. Beijing Chao Yang Hospital · 1 shared drug class
  7. Beijing Dongfang Biotech Co., Ltd. · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hangzhou Sciwind Biosciences Co., Ltd.:

Cite this brief

Drug Landscape (2026). Hangzhou Sciwind Biosciences Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hangzhou-sciwind-biosciences-co-ltd. Accessed 2026-06-10.

Related